89bio publishes results from Phase 2 ENTRIGUE trial of pegozafermin in SHTG

89bio announced that the previously reported positive data from the Phase 2 ENTRIGUE trial of pegozafermin in patients with severe hypertriglyceridemia were published online in Nature Medicine. As previously announced, ENTRIGUE met its primary endpoint of demonstrating statistically significant reductions in median triglycerides from baseline in pegozafermin-treated patients across all dose groups compared to placebo after eight weeks of treatment. Significant reductions in TGs were observed consistently across all prespecified patient subgroups, including those on lipid-modifying background therapies. Additionally, the ENTRIGUE trial met multiple secondary endpoints, showing that treatment with pegozafermin led to improvements in atherogenic lipoproteins, metabolic measures, liver fat, and markers of liver inflammation. Data from the ENTRIGUE trial show pegozafermin significantly reduced TGs after only eight weeks of treatment across all dose groups, with placebo-corrected changes from baseline ranging from -29% to -53%. In pooled data across all doses, pegozafermin lowered TG levels to less than 500 mg/dL in 80% of patients compared to 29% of patients on placebo. The trial also demonstrated that pegozafermin had positive effects on atherogenic lipids, including improvements in levels of non-HDL-C and apolipoprotein B, across the majority of patients. Importantly, reductions in both triglycerides and atherogenic lipoproteins occurred regardless of whether patients were on lipid-modifying background therapy. Additionally, robust reductions in liver fat were observed across all dose groups, as evaluated with magnetic resonance imaging – proton density fat factor, including 88% of patients who achieved a greater than or equal to30% reduction in liver fat from baseline and 24% who achieved normalized levels of liver fat after 8 weeks of treatment. Pegozafermin was well tolerated with a favorable safety profile across doses.